Alloy is Building the World’s First Fully Integrated Product Development Organization

For decades, biotech has had two ways to move a medicine forward: build every capability in-house, or rent pieces of the work from a fragmented supply chain of CROs, CDMOs, and software vendors. Each solves part of the problem. None of them builds the product.

There has only ever been one operating model that integrates all five steps (basic research, discovery, preclinical, clinical, and commercial) into a single system where every program makes the next one faster. It has lived inside the handful of companies large enough to afford it. And every one of those companies uses it to advance a pipeline of its own.

That is the quiet contradiction at the center of the industry. The only players with fully integrated development capability are also competitors to anyone who might want to use it.

We built Alloy to resolve that contradiction. Alloy is the world's first, Product Development Organization: integrated development infrastructure, proprietary data, and long-term partnership that discovers and develops medicines alongside innovators - from composition of matter through the clinic and to market. We coined the term because no existing category described what we spent the last decade building, or what we intend to become at scale.

This is not a thesis in search of proof. We have more than 220 partners. We have over 110 partnered drug programs in the hands of other companies advancing their medicine through the clinic. We already have 24 drugs in the clinic. And through our affiliated venture studio, 82VS, we have already helped create 18 new drug companies. The infrastructure works. What comes next is scaling it to the entire world.

Here is what makes a PDO new, and it is the whole point: Alloy will never have a pipeline of its own. Not now, not at scale, not ever. We do not compete with our partners. We cannot. The architecture forbids it.

If that sounds like a limitation, look at what happened in the tech industry when similar trends converged.

Twenty-five years ago, computing and hardware was fragmented and application-driven. Everyone who wanted to build something first had to build the ground they stood on - the servers, the storage, the networking. Then the hyperscalers arrived. They made a strange and disciplined promise: we will run the infrastructure for the entire world, and we will never compete with what you build on top of it. That neutrality was not a weakness. It was the reason they could scale to serve everyone, and it is why they became the most valuable companies on earth.

Biopharma is where technology was then - brilliant, fragmented, and forced to rebuild the same rails over and over. The future will be served by PDOs that are hyperscaled: infrastructure that any innovator, any founder, any pharmaceutical company, and any government can build on without owning it, and without ever wondering whose side it's on.

That last part matters more than it looks. A pipeline company can be a vendor to its partners, but it can never be pure infrastructure, because its incentives are split the moment its own program competes for the same target. A PDO has no such split. Its only business is advancing everyone else's medicines. That is what makes the trust real, and trust is the thing that lets infrastructure scale without limit.

Even nations feel this gap. Governments increasingly understand that the ability to discover and develop medicine is a matter of sovereignty - of health security, supply-chain independence, and the capacity to answer the next crisis on their own terms. But sovereign capability requires an infrastructure partner whose interests never diverge from the nation it serves. That is precisely what a PDO can be, and what no pipeline company ever could.

And now the timing is right, because of AI. Artificial intelligence will transform drug development - but only when it is paired with proprietary experimental data and the laboratory capable of generating it. AI alone is not the future. CROs alone are not the future. Software alone is not the future. The future is integrated infrastructure where AI, proprietary data, and physical lab capability continuously improve one another across every program - where the insight from one discovery compounds into the next, across silos that have never been connected before. A PDO is the only structure that can hold all three in one place and let them teach each other.

This is not just a services company. It is the infrastructure layer for curing disease - built to be neutral on purpose, built to scale to the whole world, and built to serve everyone working to defeat disease without ever competing against a single one of them.

That is the model: an ecosystem approach to integrating and accelerating drug discovery and development for all companies, countries, creators and collaborators. This is the company Alloy has been building from the beginning, and we will be scaling for the decades to come. Let's make some medicine together.